EVO:NASDAQ
Evotec SE
$2.94
arrow_downward
-1.34%(-0.040) 1 日
$2.97
arrow_upward
+0.93% (+0.027)today立会前
終了: 4月29日, 16:00:00 GMT-4 · USD
search
すべての記号
1 日
5 日
1 か月
6 か月
年初来
1 年
5 年
最大
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoEVO の上位の分析情報を生成しています...
始値
$2.96
高値
$2.98
安値
$2.90
時価総額
10.56億
平均出来高
11.94万
取引量
560.00
52 週高値
$4.80
52 週安値
$2.31
EPS
-$0.34
ベータ版
1.90
発行済株式数
3.56億
従業員数
4467
ニュース記事
ウェブの情報から
Stock Titan
·
1 時間前
Two Gates grants back Evotec push for shorter, safer TB treatment
Investing.com
·
11 時間前
Evotec nominates Wolfgang Hofmann to supervisory board
Yahoo! Finance Canada
·
1 日前
Evotec SE to Announce First Quarter 2026 Results on May 6, 2026
プロフィール
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Evotec SE について